Prodromal Schizophrenia Clinical Trial
Official title:
Early Detection and Intervention for Women At-risk of Psychosis in Hong Kong: A Randomized Controlled Trial
This study aims to examine the effectiveness of the cognitive behavioral therapy in preventing the conversion of psychosis in a sample of individuals at-risk for psychosis.
Status | Recruiting |
Enrollment | 160 |
Est. completion date | August 30, 2023 |
Est. primary completion date | August 30, 2021 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 64 Years |
Eligibility | Inclusion Criteria: - women of age 18-64 - at-risk mental state as defined by the Comprehensive Assessment of At-Risk Mental States (CAARMS) - with an informed consent - able to understand Cantonese and read/write Chinese Exclusion Criteria: - those mental conditions that requires other treatment priorities (e.g., suicidal risk, substance abuse, current or past episodes of psychotic disorder, personality disorders) - those medical conditions that severely limits participation, comprehension, or adherence to the treatment (e.g., epilepsy, dementia, terminal medical illness); - those who are receiving structured psychotherapy or counselling |
Country | Name | City | State |
---|---|---|---|
Hong Kong | University of Hong Kong | Hong Kong |
Lead Sponsor | Collaborator |
---|---|
The University of Hong Kong |
Hong Kong,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Functioning: Measured by Social and Occupational Functioning Assessment Scale (SOFAS) | Measured by Social and Occupational Functioning Assessment Scale (SOFAS). The SOFAS is an observer rating scale. Ratings should be based on subject's behavior during the last 1 month. The score ranges from 0-100. A higher score represents a better outcome. | Changes from baseline to immediate, 6- and 12-month post-intervention | |
Primary | Functioning: Measured by Role Functioning Scale (RFS) | Measured by Role Functioning Scale (RFS). The RFS is comprised of four single rating scaled for evaluating the functioning of individuals in specified areas of everyday life. The four role functions assessed are:(1)Working: productivity, (2) Independent living and self care, (3) Immediate social network relationships, and (4) Extended social network relationship. The values on each of the four scales range from 1 (minimal level of role functioning), to 7 (hypothetically optimal level of role functioning). Each of the seven points on the scales is accompanied by a behaviorally defined description. | Changes from baseline to immediate, 6- and 12-month post-intervention | |
Primary | Conversion of psychosis | Proportion of subject that convert from at-risk state to psychosis | 12-month post-intervention | |
Secondary | Positive psychotic symptoms | Measurement of positive symptoms using the Chinese version of the Psychotic Symptom Rating Scales (C-PSYRATS). It comprises of the auditory hallucinations (AHS) and delusions subscales (DS). The AHS has 11 questions and the DS consists of 6 questions, each question has the responses ranging from 0-4. The higher score represents more severe positive psychotic symptoms. | Immediate, 6- and 12-month post-intervention | |
Secondary | Beliefs about the auditory hallucination | Measured by the Beliefs About Voices Questionnaire (BAVQ-R). The BAVQ-R has 35 questions, the 4 responses range from disagree, unsure, slightly agree to strongly agree. The higher score represents more convicted belief about the voices. | Immediate, 6- and 12-month post-intervention | |
Secondary | Depressive symptoms | Measured by the Calgary Depression Scale for Schizophrenia (CDSS). The scale consists of 9 questions, each has the response ranging from 0 to 3. The higher score presents more severe depressive symptoms. | Immediate, 6- and 12-month post-intervention | |
Secondary | Social anxiety :Measured by Liebowitz Social Anxiety Scale (LSAS) | Measured by Liebowitz Social Anxiety Scale (LSAS). The LSAS consists of 24 questions, the rater has to rate from 0-3 in Fear or Anxiety domain or Avoidance domain for each of the 24 questions. The higher score represents more severe social anxiety. | Immediate, 6- and 12-month post-intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03149107 -
"Multimodal Prevention of Psychosis - Investigating Efficacy of N-Acetylcysteine and Psychotherapy in CHR-Patients"
|
Phase 3 | |
Recruiting |
NCT05131035 -
Targeting Processing Speed Deficits to Improve Social Functioning and Lower Psychosis Risk
|
N/A | |
Completed |
NCT01269710 -
Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study
|
N/A | |
Enrolling by invitation |
NCT05567848 -
Accelerated TMS in Psychosis
|
Phase 1/Phase 2 | |
Recruiting |
NCT05052853 -
Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer
|
Phase 2 | |
Recruiting |
NCT05877716 -
EPI-MINN: Targeting Cognition and Motivation - National
|
N/A | |
Completed |
NCT01597141 -
Psychosis: Early Detection, Intervention and Prevention
|
N/A | |
Completed |
NCT00169988 -
Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative Symptoms
|
N/A | |
Completed |
NCT03447548 -
Neurofeedback Training for High Risk Psychosis
|
N/A | |
Completed |
NCT06190483 -
Investigating the Role of Diazepam on Brain Function and Chemistry in Psychosis Risk
|
N/A | |
Completed |
NCT01619319 -
Effects of Cognitive Remediation on Cognition in Young People at Clinical High Risk of Psychosis
|
N/A | |
Recruiting |
NCT05167396 -
REtinal and VIsual Cortical Response in Early PSYchosis
|
N/A | |
Terminated |
NCT00169949 -
Aripiprazole Treatment of the Prodrome
|
N/A | |
Recruiting |
NCT04338152 -
Family-Focused Therapy for Individuals at High Clinical Risk for Psychosis: A Confirmatory Efficacy Trial
|
N/A | |
Recruiting |
NCT05142735 -
Effects of NAC on Symptoms of CHR Patients
|
N/A | |
Enrolling by invitation |
NCT05532683 -
Feasibility Trial of a Lifestyle Intervention for CHR-P
|
N/A | |
Enrolling by invitation |
NCT03970005 -
Evaluation of Step-Based Care for Individuals at Clinical High Risk for Psychosis
|